Weekly Digest – October 2026 Weekly Digest – October 2026 22 October 2026: Enhertu approved in China for previously treated patients with HER2+ metastatic Solid tumors Daiichi Sankyo and AstraZeneca announced that Enhertu has received conditional approval in China as […]
Weekly Digest – October 2026 Weekly Digest – October 2026 23 October 2026: European Commission expands PADCEV + Keytruda approval to resectable MIBC, regardless of cisplatin eligibility Astellas announced that the European Commission has expanded the approval of PADCEV plus […]
Weekly Digest – October 2026 Weekly Digest – October 2026 21 October 2026: Samsung Bioepis receives FDA FTD for SBE303 for the treatment of Urothelial cancer Samsung Bioepis announced that the U.S. FDA has granted Fast Track Designation to SBE303, […]
Weekly Digest – October 2026 Weekly Digest – October 2026 20 October 2026: Medicovestor announces FDA FTD for MC001, a first-in-class ADC for Pancreatic cancer Medicovestor announced that the U.S. FDA has granted Fast Track Designation to MC001, its investigational […]
Weekly Digest – October 2026 Weekly Digest – October 2026 19 October 2026: Hansoh Pharma announces strategic collaboration and license agreement with Roche to advance novel ADC portfolio Hansoh Pharma announced a strategic collaboration and licensing agreement with Roche to […]
Weekly Digest – October 2026 Weekly Digest – October 2026 22 October 2026: BioNTech and Gilead partner to evaluate Pumitamig plus Trodelvy in 1L TNBC BioNTech announced a clinical trial collaboration and supply agreement with Gilead Sciences to evaluate pumitamig […]
